Galecto, Inc. Common Stock
GLTOGalecto, Inc. (GLTO) is a biotechnology company focused on developing and commercializing treatments for fibrosis and cancer. It specializes in small molecule therapeutics targeting galectin proteins, which play a role in various pathological processes. The company's therapies aim to address unmet medical needs in diseases characterized by fibrosis and tumor progression.
Company News
Galecto Inc. acquired Damora Therapeutics, expanding its blood cancer pipeline and securing $284.9 million in funding through a private placement, with plans to advance multiple therapeutic programs targeting myeloproliferative neoplasms and acute myeloid leukemia.
Galecto acquired Damora Therapeutics, a biotechnology company developing therapies for myeloproliferative neoplasms, in a transaction accompanied by a $285 million private investment that positions the company to advance potentially breakthrough treatments for blood cancers.
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nvidia was the subject of two bullish analyst notes on Tuesday.
